Gallium nitrate: the second metal with clinical activity.

Area of Science:

• Oncology
• Pharmacology
• Nephrology

Background:

• Gallium nitrate, a heavy metal salt, exhibits antitumor activity across various murine tumor models.
• Preclinical toxicology studies in multiple animal species identified the renal system as the dose-limiting organ.
• The kidneys are the primary route for gallium nitrate excretion, with significant elimination within 24 hours.

Purpose of the Study:

• To evaluate the antitumor efficacy of gallium nitrate in preclinical and early-phase human studies.
• To determine appropriate dosing regimens and assess toxicity profiles for clinical application.
• To investigate the potential of gallium nitrate in managing cancer-related hypercalcemia.

Main Methods:

• Extensive preclinical testing in diverse murine tumor models.
• Dose-ranging Phase I clinical trials to establish safety and tolerability.
• Phase II clinical evaluations in patients with refractory lymphomas and small cell lung carcinoma.

Main Results:

• Demonstrated antitumor activity in multiple animal cancer models.
• Phase I studies suggested several viable Phase II dosing schedules.
• Observed objective response rates of 28% in refractory lymphomas and 11% in small cell lung carcinoma.
• Effective in treating cancer-related hypercalcemia by inhibiting bone calcium reabsorption.

Conclusions:

• Gallium nitrate possesses significant antitumor potential and is effective in managing hypercalcemia.
• Renal toxicity is manageable through hydration and osmotic diuresis or continuous infusion schedules.
• Further Phase II studies are ongoing across various major tumor types.